Management of Dyslipidemia in HIV-infected Patients

Overview

Journal Clin Lipidol

Date 2012 Jan 5

PMID 22216062

Citations 12

Authors

Carlos D Malvestutto

Judith A Aberg

Affiliations

Soon will be listed here.

Abstract

Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. As this population lives longer, coronary heart disease has become an important comorbid condition. Dyslipidemia in HIV-infected individuals is a complex condition, with multiple contributing factors including the HIV virus itself, individual genetic characteristics and antiretroviral therapy-induced metabolic changes. Effective management of dyslipidemia in this population is essential to reduce cardiovascular risk but presents multiple challenges due to interactions between antiretroviral therapy agents and lipid-lowering medications.

Citing Articles

Apolipoprotein E genetic variation, atherogenic index and cardiovascular disease risk assessment in an African population: An analysis of HIV and malaria patients in Ghana.

Thomford N, Anyanful A, Ateko R, Blackhurst D, Biney R, Boadi D PLoS One. 2023; 18(5):e0284697.

PMID: 37134097 PMC: 10155972. DOI: 10.1371/journal.pone.0284697.

Subclinical Atherosclerosis Is Associated with Discrepancies in BAFF and APRIL Levels and Altered Breg Potential of Precursor-like Marginal Zone B-Cells in Long-Term HIV Treated Individuals.

Aranguren M, Doyon-Laliberte K, El-Far M, Chartrand-Lefebvre C, Routy J, Barril J Vaccines (Basel). 2023; 11(1).

PMID: 36679926 PMC: 9863280. DOI: 10.3390/vaccines11010081.

The Incidence and Risk Factors of Renal Insufficiency among Korean HIV infected Patients: The Korea HIV/AIDS Cohort Study.

Kim J, Jang H, Kim J, Song J, Kim S, Kim S Infect Chemother. 2022; 54(3):534-541.

PMID: 36196611 PMC: 9533162. DOI: 10.3947/ic.2022.0101.

Atherosclerosis in HIV Patients: What Do We Know so Far?.

Poznyak A, Bezsonov E, Borisov E, Grechko A, Kartuesov A, Orekhov A Int J Mol Sci. 2022; 23(5).

PMID: 35269645 PMC: 8910073. DOI: 10.3390/ijms23052504.

Immunosuppression and HIV Viremia Associated with More Atherogenic Lipid Profile in Older People with HIV.

Levy M, Greenberg A, Magnus M, Younes N, Castel A AIDS Res Hum Retroviruses. 2018; 35(1):81-91.

PMID: 30353737 PMC: 6343189. DOI: 10.1089/AID.2018.0145.

References

Moyle G, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard B . Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS. 2001; 15(12):1503-8. DOI: 10.1097/00002030-200108170-00007. View

Busti A, Bain A, Hall 2nd R, Bedimo R, Leff R, Meek C . Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008; 51(6):605-10. DOI: 10.1097/FJC.0b013e31817b5b5a. View

Ribaudo H, Benson C, Zheng Y, Koletar S, Collier A, Lok J . No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011; 52(7):929-40. PMC: 3062545. DOI: 10.1093/cid/ciq244. View

Bonnet E, Bernard J, Fauvel J, Massip P, Ruidavets J, Perret B . Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients. AIDS Res Hum Retroviruses. 2008; 24(2):169-71. DOI: 10.1089/aid.2007.0076. View

. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251(3):351-64. DOI: 10.1001/jama.1984.03340270029025. View

Lennox J, DeJesus E, Berger D, Lazzarin A, Pollard R, Madruga J . Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010; 55(1):39-48. PMC: 6065510. DOI: 10.1097/QAI.0b013e3181da1287. View

Mujawar Z, Rose H, Morrow M, Pushkarsky T, Dubrovsky L, Mukhamedova N . Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006; 4(11):e365. PMC: 1629034. DOI: 10.1371/journal.pbio.0040365. View

Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga J, Molina J . Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009; 23(17):2289-300. DOI: 10.1097/QAD.0b013e3283316a5e. View

Thomas J, Lopes-Virella M, Del Bene V, Cerveny J, Taylor K, McWhorter L . Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy. 2000; 20(6):727-34. DOI: 10.1592/phco.20.7.727.35179. View

10.

Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View

11.

Caramelli B, de Bernoche C, Sartori A, Sposito A, Santos R, Monachini M . Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis. 2002; 5(6):332-8. DOI: 10.1590/s1413-86702001000600007. View

12.

Friis-Moller N, Reiss P, Sabin C, Weber R, Monforte A, El-Sadr W . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356(17):1723-35. DOI: 10.1056/NEJMoa062744. View

13.

Jacobson T . Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol. 2009; 5(9):507-18. DOI: 10.1038/nrendo.2009.151. View

14.

Gordon D, Probstfield J, Garrison R, Neaton J, CASTELLI W, Knoke J . High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989; 79(1):8-15. DOI: 10.1161/01.cir.79.1.8. View

15.

Aboulafia D, Johnston R . Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDS. 2002; 14(1):13-8. DOI: 10.1089/108729100318091. View

16.

Grennan T, Walmsley S . Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class. J Int Assoc Physicians AIDS Care (Chic). 2009; 8(6):354-63. DOI: 10.1177/1545109709347373. View

17.

Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S . Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2006; 115(4):450-8. DOI: 10.1161/CIRCULATIONAHA.106.637793. View

18.

Kastelein J, Akdim F, Stroes E, Zwinderman A, Bots M, Stalenhoef A . Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358(14):1431-43. DOI: 10.1056/NEJMoa0800742. View

19.

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray K, Thompson A . Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302(18):1993-2000. PMC: 3284229. DOI: 10.1001/jama.2009.1619. View

20.

Kris-Etherton P, Harris W, Appel L . Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003; 23(2):151-2. DOI: 10.1161/01.atv.0000057393.97337.ae. View